SCHEMBL10269196

SCHEMBL10269196

COc1ccc(NC(=O)c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.50
RAB9A P51151 8/20 0.50
CASP3 P42574 2/20 0.50
SENP7 Q9BQF6 2/20 0.50
MAPKAPK2 P49137 4/20 0.47
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDR P35968 2/20 0.45
PDGFRB P09619 1/20 0.45
SENP8 Q96LD8 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
PSMB11 A5LHX3 1/20 0.42
PSMA7 O14818 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10269040 0.91 NPC1 (0.50) NPC1RAB9AMAPKAPK2MAPTMEN1
SCHEMBL10269197 0.89 MAPKAPK2 (0.52) NPC1RAB9AMAPKAPK2KDRPDGFRB
SCHEMBL10269655 0.88 MEN1 (0.51) MAPKAPK2MAPTMEN1KMT2AALDH1A1
SCHEMBL10269330 0.85 NPC1 (0.47) NPC1RAB9AMAPKAPK2MAPTMEN1
SCHEMBL10269334 0.85 MAP4K4 (0.51) NPC1RAB9AMAPKAPK2MAPTALDH1A1
SCHEMBL10269329 0.85 NPC1 (0.58) NPC1RAB9AMAPKAPK2DYRK3ROCK2
SCHEMBL10269335 0.84 MAPKAPK2 (0.48) NPC1RAB9AMAPKAPK2ALDH1A1SMN1; SMN2
SCHEMBL10269605 0.84 MAPKAPK2 (0.49) NPC1RAB9AMAPKAPK2MEN1KMT2A
SCHEMBL10269338 0.84 MEN1 (0.48) MAPKAPK2MAPTMEN1KMT2AALDH1A1
SCHEMBL10269034 0.84 ALDH1A1 (0.55) NPC1RAB9AMAPKAPK2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 NPC1 58/4885RAB9A 740/4885CASP3 409/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 NPC1 58/4885RAB9A 740/4885CASP3 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.